Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-8 of 8 for your search:
Drug:
trabectedin
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
A Study to Provide Access to Trabectedin in Patients With Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CR003583
, SAR-3002, ET743SAR3002, NCT00210665
2.
A Study of Effectiveness of Trabectedin for the Treatment of Patient With Specific Subtypes of Metastatic Breast Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CR014764
, NCT00580112
3.
A Study of the Safety and Effectiveness of Trabetedin Versus Doxorubicin-Based Chemotherapy in Patients With Translocation-Related Sarcomas (TRS)
Phase:
Phase III
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CR015769
, NCT00796120
4.
A Placebo-Controlled Study Evaluating the Potential Effects of Trabectedin on the Heart in Patients With Advanced Cancer
Phase:
Phase II, Phase I
Type:
Supportive care, Treatment
Status:
Active
Age:
18 to 65
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CR014917
, NCT00786838
5.
Phase II Study of Ecteinascidin 743 in Pediatric Patients With Recurrent or Refractory Soft Tissue Sarcomas or Ewing's Sarcoma Family of Tumors
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
1 to 21 (at time of diagnosis)
Sponsor:
NCI
Protocol IDs:
COG-ADVL0221
, NCT00070109, ADVL0221
6.
ET-743 in Men With Advanced Prostate Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
ET-B-025-02
, NCT00072670
7.
Phase II Study of Docetaxel and Trabectedin With Growth Factor Support as Third-Line Therapy in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
GOG-0186F
, GOG-0186F, NCT00569673
8.
Phase I Study of Trabectedin in Pediatric Patients With Relapsed or Refractory Solid Tumors
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
4 to 16
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0054
, NCT00437047
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute